2024

• Carroll, A., Park, S., Lin, C., Taylor, M., Kwok, F., Simon, N., Reilly, M., Kiernan, M., Vucic, S. (2024). Axonal excitability as an early biomarker of nerve involvement in hereditary transthyretin amyloidosis. Clinical Neurophysiology, 159, 81-95. [More Information]
• Tu, S., Li, T., Carroll, A., Mahoney, C., Huynh, W., Park, S., Henderson, R., Vucic, S., Kiernan, M., Lin, C. (2024). Central neurodegeneration in Kennedy’s disease accompanies peripheral motor dysfunction. Scientific Reports, 14(1). [More Information]
• Li, T., Trinh, T., Bosco, A., Kiernan, M., Goldstein, D., Park, S. (2024). Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Supportive Care in Cancer, 32(5), 278. [More Information]
• Alberti, P., Li, T., Park, S., Nathan, P., Tamburin, S., Thomas, S., Smith, E., Argyriou, A., Bruna, J., Damaj, M., et al (2024). Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)—a white paper. Supportive Care in Cancer, 32(2), 117. [More Information]
• Choi, V., Park, S., Lacey, J., Kumar, S., Heller, G., Grimison, P. (2024). Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: Protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN). BMJ Open, 14(1). [More Information]
• Mahfouz, F., Li, T., Timmins, H., Horvath, L., Harrison, M., Grimison, P., Marx, G., Goldstein, D., Park, S. (2024). Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity. JNCCN Journal of the National Comprehensive Cancer Network, 22(2), 108-116. [More Information]
• Yeung, N., Li, T., Lin, H., Timmins, H., Goldstein, D., Harrison, M., Friedlander, M., Mahon, K., Giles, C., Meikle, P., Park, S., Horvath, L. (2024). Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy. JCO Precision Oncology, 8. [More Information]
• Timmins, H., Mok, V., Kim, S., Shahrizaila, N., Sung, J., Sobue, G., Agustini, S., Ward, S., Anstey, K., Talbot, D., Tu, S., Tan, R., Lin, C., O'Callaghan, C., Michaelian, J., Jeon, Y., Foxe, D., Naismith, S., Piguet, O., Ahmed, R., Devenney, E., Park, S., Kiernan, M., et al (2024). Regional health priorities for dementia: a roadmap for the Western Pacific. The Lancet Regional Health. Western Pacific, 50, 101179. [More Information]

2023

• Park, S., Cetinkaya-Fisgin, A., Argyriou, A., Hoke, A., Cavaletti, G., Alberti, P. (2023). Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: Clinical and experimental evidence. Journal of Neurology, Neurosurgery and Psychiatry, 94(11), 962-972. [More Information]
• Timmins, H., Mizrahi, D., Li, T., Kiernan, M., Goldstein, D., Park, S. (2023). Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. Journal of Cancer Survivorship, 17(1), 222-236. [More Information]
• Li, T., Timmins, H., Trinh, T., Mizrahi, D., Harrison, M., Horvath, L., Grimison, P., Friedlander, M., Kiernan, M., King, M., Rutherford, C., Park, S., et al (2023). Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes. JNCCN Journal of the National Comprehensive Cancer Network, 21(2), 125-132. [More Information]
• Mizrahi, D., Goldstein, D., Trinh, T., Li, T., Timmins, H., Harrison, M., Marx, G., Hovey, E., Lewis, C., Friedlander, M., Park, S. (2023). Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy. Asia-Pacific Journal of Clinical Oncology, 19(1), 243-249. [More Information]
• Li, T., Kandula, T., Cohn, R., Kiernan, M., Park, S., Farrar, M. (2023). Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia. Clinical Neurophysiology, 154, 157-168. [More Information]
• White, D., Abdulla, M., Park, S., Goldstein, D., Moalem-Taylor, G., Lees, J. (2023). Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System. [More Information]

2022

• Li, T., Park, S., Battaglini, E., King, M., Kiernan, M., Goldstein, D., Rutherford, C. (2022). Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. Quality of Life Research, 31(11), 3091-3107. [More Information]
• Mahfouz, F., Park, S., Li, T., Timmins, H., Horvath, L., Harrison, M., Grimison, P., King, T., Goldstein, D., Mizrahi, D. (2022). Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients. Clinical Autonomic Research, 32(6), 497-506. [More Information]
• Mizrahi, D., Goldstein, D., Kiernan, M., Robinson, L., Pitiyarachchi, O., McCullough, S., Mendoza-Jones, P., Grimison, P., Boyle, F., Park, S. (2022). Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 30(7), 5965-5974. [More Information]
• Carroll, A., Howells, J., Lin, C., Park, S., Simon, N., Reilly, M., Vucic, S., Kiernan, M. (2022). Differences in nerve excitability properties across upper limb sensory and motor axons. Clinical Neurophysiology, 136, 138-149. [More Information]
• Bérubé-Mercier, P., Tapp, D., Cimon, M., Li, T., Park, S., Bouhêlier, É., McGarragle, K., Robichaud, L., Gewandter, J., Bouchard, M., et al (2022). Evaluation of the psychometric properties of patient-reported and clinician-reported outcome measures of chemotherapy-induced peripheral neuropathy: a COSMIN systematic review protocol. BMJ Open, 12(4), e057950-1-e057950-7. [More Information]
• Chung, K., Park, S., Streckmann, F., Wiskemann, J., Mohile, N., Kleckner, A., Colloca, L., Dorsey, S., Kleckner, I. (2022). Mechanisms, Mediators, and Moderators of the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy. Cancers, 14(5), 1224. [More Information]
• Park, S., Tamburin, S., Schenone, A., Kleckner, I., Velasco, R., Alberti, P., Kanzawa-Lee, G., Lustberg, M., Dorsey, S., Mantovani, E., et al (2022). Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. Expert Review of Neurotherapeutics, 22(1), 65-76. [More Information]
• Hooshmand, K., Goldstein, D., Timmins, H., Li, T., Harrison, M., Friedlander, M., Lewis, C., Lees, J., Moalem-Taylor, G., Guennewig, B., Park, S., Kwok, J. (2022). Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. Journal of Translational Medicine, 20(1). [More Information]
• Park, S., Li, T., Kiernan, M., Garg, N., Wilson, I., White, R., Boggild, M., McNabb, A., Lee-Archer, M., Taylor, B. (2022). Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia. Muscle and Nerve, 66(5), 576-582. [More Information]
• Tamburin, S., Park, S., Schenone, A., Mantovani, E., Hamedani, M., Alberti, P., Yildiz-Kabak, V., Kleckner, I., Kolb, N., Mazzucchelli, M., et al (2022). Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Critical Reviews in Oncology / Hematology (online), 171, 103575. [More Information]
• Chiang, J., Khou, V., Tavakoli, A., Park, S., Goldstein, D., Krishnan, A., Markoulli, M. (2022). Reproducibility and Reliability of Subbasal Corneal Nerve Parameters of the Inferior Whorl in the Neurotoxic and Healthy Cornea. Cornea, 41(12), 1487-1494. [More Information]
• Chiang, J., Goldstein, D., Trinh, T., Au, K., Park, S., Krishnan, A., Markoulli, M. (2022). Tear film substance P in patients treated with neurotoxic chemotherapy. Experimental Eye Research, 224. [More Information]

2021

• Chiang, J., Goldstein, D., Trinh, T., Au, K., Park, S., Krishnan, A., Markoulli, M. (2021). A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. Scientific Reports, 11(1), 1-10. [More Information]
• Chiang, J., Goldstein, D., Trinh, T., Au, K., Mizrahi, D., Muhlmann, M., Crowe, P., O’neill, S., Edwards, K., Park, S., et al (2021). A cross-sectional study of sub-basal corneal nerve reduction following neurotoxic chemotherapy. Translational Vision Science and Technology, 10(1), 1-11. [More Information]
• Mitchell, L., Shen, C., Timmins, H., Park, S., New, E. (2021). A Versatile Fluorescent Sensor Array for Platinum Anticancer Drug Detection in Biological Fluids. ACS Sensors, 6(3), 1261-1269. [More Information]
• Smith, E., Kuisell, C., Cho, Y., Kanzawa-Lee, G., Gilchrist, L., Park, S., Scott, M., Alberti, P. (2021). Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review. Cancer Treatment and Research Communications, 28, 100420. [More Information]
• Li, T., Mizrahi, D., Goldstein, D., Kiernan, M., Park, S. (2021). Chemotherapy and peripheral neuropathy. Neurological Sciences, 42(10), 4109-4121. [More Information]
• Battaglini, E., Goldstein, D., Grimison, P., McCullough, S., Mendoza-Jones, P., Park, S. (2021). Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. JNCCN Journal of the National Comprehensive Cancer Network, 19(7), 821-828. [More Information]
• Kleckner, I., Park, S., Streckmann, F., Wiskemann, J., Hardy, S., Mohile, N. (2021). Clinical and Practical Recommendations in the Use of Exercise, Physical Therapy, and Occupational Therapy for Chemotherapy-Induced Peripheral Neuropathy. In Maryam Lustberg, Charles Loprinzi (Eds.), Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy: A MASCC Book, (pp. 243-252). Cham: Springer. [More Information]
• Yu, A., Street, D., Viney, R., Goodall, S., Pearce, A., Haywood, P., Haas, M., Battaglini, E., Goldstein, D., Timmins, H., Park, S. (2021). Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. Supportive Care in Cancer, 29(11), 6379-6387. [More Information]
• Chiang, J., Goldstein, D., Tavakoli, A., Trinh, T., Klisser, J., Lewis, C., Friedlander, M., Naduvilath, T., Au, K., Park, S., et al (2021). Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. Scientific Reports, 11(1), 22884. [More Information]
• Chiang, J., Goldstein, D., Park, S., Krishnan, A., Markoulli, M. (2021). Corneal nerve changes following treatment with neurotoxic anticancer drugs. The Ocular Surface, 21, 221-237. [More Information]
• Lees, J., Abdulla, M., Barkl-Luke, M., Livni, L., Keating, B., Hayes, J., Fiore, N., Park, S., Moalem-Taylor, G., Goldstein, D. (2021). Effect of exercise on neuromuscular toxicity in oxaliplatin-treated mice. Muscle and Nerve, 64(2), 225-234. [More Information]
• Park, S., Renn, C., Lees, J., Dorsey, S., Cavaletti, G., Carozzi, V. (2021). Electrophysiological Assessments in Peripheral Nerves and Spinal Cord in Rodent Models of Chemotherapy-Induced Painful Peripheral Neuropathy. In Jordi Llorens, Marta Barenys (Eds.), Experimental Neurotoxicology Methods, (pp. 133-161). New York: Humana Press. [More Information]
• Menant, J., Goldstein, D., Au, K., Trinh, T., van Schooten, K., McCrary, J., Harris, C., Forster, B., Park, S. (2021). Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy. Gait and Posture, 89, 178-185. [More Information]
• Mizrahi, D., Park, S., Li, T., Timmins, H., Trinh, T., Au, K., Battaglini, E., Wyld, D., Henderson, R., Grimison, P., et al (2021). Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Network Open, 4(2), e2036695. [More Information]
• Trinh, T., Park, S., Murray, J., Pickering, H., Lin, C., Martin, A., Friedlander, M., Kiernan, M., Goldstein, D., Krishnan, A. (2021). Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. Supportive Care in Cancer, 29(2), 1103-1110. [More Information]
• Hertz, D., Childs, D., Park, S., Faithfull, S., Ke, Y., Ali, N., McGlown, S., Chan, A., Grech, L., Loprinzi, C., et al (2021). Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews, 99, 102241. [More Information]
• Alberti, P., Bernasconi, D., Cornblath, D., Merkies, I., Park, S., Velasco, R., Bruna, J., Psimaras, D., Koeppen, S., Pace, A., et al (2021). Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity. Neurology, 97(7), E660-E672. [More Information]
• Kleckner, I., Park, S., Streckmann, F., Wiskemann, J., Hardy, S., Mohile, N. (2021). Systematic Review of Exercise for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. In Maryam Lustberg, Charles Loprinzi (Eds.), Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy: A MASCC Book, (pp. 183-241). Cham: Springer. [More Information]
• Timmins, H., Li, T., Goldstein, D., Trinh, T., Mizrahi, D., Harrison, M., Horvath, L., Friedlander, M., Kiernan, M., Park, S. (2021). The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. Journal of Cancer Survivorship, 16(2), 223-232.
• Timmins, H., Li, T., Trinh, T., Kiernan, M., Harrison, M., Boyle, F., Friedlander, M., Goldstein, D., Park, S. (2021). Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. The Oncologist, 26(5), 366-374. [More Information]

2020

• Makker, P., White, D., Lees, J., Parmar, J., Goldstein, D., Park, S., Howells, J., Moalem-Taylor, G. (2020). Acute changes in nerve excitability following oxaliplatin treatment in mice. Journal of Neurophysiology, 124(1), 232-244. [More Information]
• Smith, E., Kuisell, C., Kanzawa-Lee, G., Bridges, C., Alberti, P., Cavaletti, G., Saad, R., Park, S. (2020). Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review. The Lancet Haematology, 7(5), e408-e417. [More Information]
• Kandula, T., Farrar, M., Cohn, R., Carey, K., Johnston, K., Kiernan, M., Krishnan, A., Park, S. (2020). Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. Clinical Neurophysiology, 131(4), 783-790. [More Information]
• Li, T., Timmins, H., King, T., Kiernan, M., Goldstein, D., Park, S. (2020). Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. Hematological Oncology, 38(3), 229-243. [More Information]
• Timmins, H., Li, T., Huynh, W., Kiernan, M., Baron-Hay, S., Boyle, F., Goldstein, D., Park, S. (2020). Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Clinical Neurophysiology, 131(8), 1979-1985. [More Information]
• Argyriou, A., Bruna, J., Park, S., Cavaletti, G. (2020). Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Review of Neurotherapeutics, 20(10), 1005-1016. [More Information]
• Timmins, H., Li, T., Park, S. (2020). Evaluation of Neuropathic Pain in Chemotherapy Treated Patients. In Wolfgang Grisold, Riccardo Soffietti, Stefan Oberndorfer and Guido Cavaletti (Eds.), Effects of Cancer Treatment on the Nervous System, Volume 1, (pp. 255-280). United Kingdom: Cambridge Scholars Publishing.
• Park, S., Thurbon, R., Kiernan, M. (2020). Isaacs syndrome: The frontier of neurology, psychiatry, immunology and cancer. Journal of Neurology, Neurosurgery and Psychiatry, 91(12), 1243-1244. [More Information]
• Kiernan, M., Bostock, H., Park, S., Kaji, R., Krarup, C., Krishnan, A., Kuwabara, S., Lin, C., Misawa, S., Moldovan, M., Vucic, S., Burke, D., et al (2020). Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 131(1), 308-323. [More Information]
• Kandula, T., Park, S., Carey, K., Lin, C., Farrar, M. (2020). Peripheral nerve maturation and excitability properties from early childhood: Comparison of motor and sensory nerves. Clinical Neurophysiology, 131(10), 2452-2459. [More Information]
• Li, T., Timmins, H., Lazarus, H., Park, S. (2020). Peripheral neuropathy in hematologic malignancies – Past, present and future. Blood Reviews, 43, 100653. [More Information]
• Timmins, H., Li, T., Kiernan, M., Horvath, L., Goldstein, D., Park, S. (2020). Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. The Journal of Pain, 21(1-Feb), 44-58. [More Information]
• Timmins, H., Li, T., Kiernan, M., Baron-Hay, S., Marx, G., Boyle, F., Goldstein, D., Park, S. (2020). Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Supportive Care in Cancer, 28(9), 4459-4466. [More Information]
• Chiang, J., Zahari, I., Markoulli, M., Krishnan, A., Park, S., Semmler, A., Goldstein, D., Edwards, K. (2020). The impact of anticancer drugs on the ocular surface. The Ocular Surface, 18(3), 403-417. [More Information]

2019

• Geevasinga, N., Howells, J., Menon, P., van den Bos, M., Shibuya, K., Matamala, J., Park, S., Byth, K., Kiernan, M., Vucic, S. (2019). Amyotrophic lateral sclerosis diagnostic index: Toward a personalized diagnosis of ALS. Neurology, 92(6), e536-e547. [More Information]
• McCrary, J., Goldstein, D., Trinh, T., Timmins, H., Li, T., Menant, J., Friedlander, M., Lewis, C., Hertzberg, M., O’Neill, S., King, T., Park, S., et al (2019). Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. JNCCN Journal of the National Comprehensive Cancer Network, 17(8), 949-955. [More Information]
• Tan, A., McCrary, J., Park, S., Trinh, T., Goldstein, D. (2019). Chemotherapy-induced peripheral neuropathy - patient-reported outcomes compared with NCI-CTCAE grade. Supportive Care in Cancer, 27(12), 4771-4777. [More Information]
• Garg, N., Park, S., Howells, J., Vucic, S., Yiannikas, K., Mathey, E., Nguyen, T., Noto, Y., Barnett, M., Pollard, J., Kiernan, M. (2019). Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy. European Journal of Neurology, 26(8), 1121-1129. [More Information]
• McCrary, J., Goldstein, D., Sandler, C., Barry, B., Marthick, M., Timmins, H., Li, T., Horvath, L., Grimison, P., Park, S. (2019). Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 27(10), 3849-3857. [More Information]
• Argyriou, A., Antonacopoulou, A., Alberti, P., Briani, C., Bruna, J., Velasco, R., Anastopoulou, G., Park, S., Cavaletti, G., Kalofonos, H. (2019). Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 24(4), 298-303. [More Information]
• McCrary, J., Goldstein, D., Wyld, D., Henderson, R., Lewis, C., Park, S. (2019). Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. Journal of Cancer Survivorship, 13(4), 495-502. [More Information]
• Argyriou, A., Park, S., Islam, B., Tamburin, S., Velasco, R., Alberti, P., Bruna, J., Psimaras, D., Cavaletti, G., Cornblath, D. (2019). Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. Journal of Neurology, Neurosurgery and Psychiatry, 90(12), 1361-1369. [More Information]
• McCrary, J., Goldstein, D., Trinh, T., Timmins, H., Li, T., Friedlander, M., Bosco, A., Harrison, M., Maier, N., O'Neill, S., Park, S. (2019). Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 58(6), 1023-1032. [More Information]
• Park, S., Alberti, P., Kolb, N., Gewandter, J., Schenone, A., Argyriou, A. (2019). Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 24(Suppl 2), S13-S25. [More Information]
• Tamburin, S., Park, S., Alberti, P., Demichelis, C., Schenone, A., Argyriou, A. (2019). Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 24(Suppl 2), S40-S51. [More Information]
• Argyriou, A., Cavaletti, G., Park, S. (2019). The Toxic Neuropathy Consortium of the Peripheral Nerve Society. Journal of the Peripheral Nervous System, 24(Suppl 2), S4-S5. [More Information]
• Argyriou, A., Park, S., Bruna, J., Cavaletti, G. (2019). Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 24(4), 360-361. [More Information]

2018

• Battaglini, E., Park, S., Barnes, E., Goldstein, D. (2018). A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. Contemporary Clinical Trials, 70, 135-138. [More Information]
• Makker, P., Matamala, J., Park, S., Lees, J., Kiernan, M., Burke, D., Moalem-Taylor, G., Howells, J. (2018). A unified model of the excitability of mouse sensory and motor axons. Journal of the Peripheral Nervous System, 23(3), 159-173. [More Information]
• Garg, N., Park, S., Howells, J., Noto, Y., Vucic, S., Yiannikas, C., Tomlinson, S., Huynh, W., Simon, N., Mathey, E., Spies, J., Pollard, J., Kiernan, M., et al (2018). Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 129(10), 2162-2169. [More Information]
• Kandula, T., Farrar, M., Cohn, R., Mizrahi, D., Carey, K., Johnston, K., Kiernan, M., Krishnan, A., Park, S. (2018). Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes. JAMA Neurology, 75(8), 980-988. [More Information]
• Noto, Y., Garg, N., Li, T., Timmins, H., Park, S., Shibuya, K., Shahrizaila, N., Huynh, W., Matamala, J., Dharmadasa, T., Yiannikas, K., Vucic, S., Kiernan, M. (2018). Comparison of cross-sectional areas and distal-proximal nerve ratios in amyotrophic lateral sclerosis. Muscle and Nerve, 58(6), 777-783. [More Information]
• Noto, Y., Simon, N., Selby, A., Garg, N., Shibuya, K., Shahrizaila, N., Huynh, W., Matamala, J., Dharmadasa, T., Park, S., Vucic, S., Kiernan, M. (2018). Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. Clinical Neurophysiology, 129(5), 974-980. [More Information]
• Matamala, J., Howells, J., Dharmadasa, T., Huynh, W., Park, S., Burke, D., Kiernan, M. (2018). Excitability of sensory axons in amyotrophic lateral sclerosis. Clinical Neurophysiology, 129(7), 1472-1478. [More Information]
• Howells, J., Matamala, J., Park, S., Garg, N., Vucic, S., Bostock, H., Burke, D., Kiernan, M. (2018). In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis. Journal of Physiology, 596(22), 5379-5396. [More Information]
• Garg, N., Park, S., Kiernan, M. (2018). Inflammatory neuropathies: all shapes and sizes. Journal of Neurology, Neurosurgery and Psychiatry, 89(11), 1128. [More Information]
• Kandula, T., Farrar, M., Krishnan, A., Murray, J., Timmins, H., Goldstein, D., Lin, C., Kiernan, M., Park, S. (2018). Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve, 57(4), 615-621. [More Information]
• Garg, N., Park, S., Yiannikas, K., Vucic, S., Howells, J., Noto, Y., Mathey, E., Pollard, J., Kiernan, M. (2018). Neurofascin-155 IgG4 Neuropathy: Pathophysiological insights, spectrum of clinical severity and response to treatment. Muscle and Nerve, 57(5), 848-851. [More Information]
• Park, S., Kiernan, M. (2018). Oxaliplatin and neuropathy: A role for sodium channels. Clinical Neurophysiology, 129(3), 670-671. [More Information]
• Howells, J., Bostock, H., Park, S., Kiernan, M., Burke, D. (2018). Tracking small sensory nerve action potentials in human axonal excitability studies. Journal of Neuroscience Methods, 298, 45-53. [More Information]

2017

• Mathey, E., Garg, N., Park, S., Nguyen, T., Baker, S., Yuki, N., Yiannikas, K., Lin, C., Spies, J., Ghaoui, R., Barnett, M., Vucic, S., Pollard, J., Kiernan, M. (2017). Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of Neuroimmunology, 309, 41-46. [More Information]
• Park, S., Kiernan, M., Vucic, S. (2017). Axonal Excitability in Amyotrophic Lateral Sclerosis: Axonal Excitability in ALS. Neurotherapeutics, 14(1), 78-90. [More Information]
• Timmins, H., Saw, W., Cheah, B., Lin, C., Vucic, S., Ahmed, R., Kiernan, M., Park, S. (2017). Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 56(4), 721-725. [More Information]
• Makker, P., Duffy, S., Lees, J., Perera, C., Tonkin, R., Butovsky, O., Park, S., Goldstein, D., Moalem-Taylor, G. (2017). Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PloS One, 12(1), 1-24. [More Information]
• Park, S., Kwok, J., Asher, R., Lee, C., Beale, P., Selle, F., Friedlander, M. (2017). Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial. Annals of Oncology, 28(11), 2733-2740. [More Information]
• Garg, N., Park, S., Vucic, S., Yiannikas, C., Spies, J., Howells, J., Huynh, W., Matamala, J., Krishnan, A., Pollard, J., Kiernan, M., et al (2017). Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 88(6), 474-483. [More Information]
• Farrar, M., Park, S., Vucic, S., Carey, K., Turner, B., Gillingwater, T., Swoboda, K., Kiernan, M. (2017). Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 81(3), 355-368. [More Information]
• Lees, J., Makker, P., Tonkin, R., Abdulla, M., Park, S., Goldstein, D., Moalem-Taylor, G. (2017). Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. European Journal of Cancer, 73, 22-29. [More Information]
• Shibuya, K., Park, S., Howells, J., Huynh, W., Noto, Y., Shahrizaila, N., Matamala, J., Vucic, S., Kiernan, M. (2017). Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 55(3), 424-427. [More Information]
• Garg, N., Howells, J., Yiannikas, C., Vucic, S., Krishnan, A., Spies, J., Bostock, H., Mathey, E., Pollard, J., Park, S., Kiernan, M. (2017). Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 128(10), 2022-2028. [More Information]
• Kandula, T., Farrar, M., Kiernan, M., Krishnan, A., Goldstein, D., Horvath, L., Grimison, P., Boyle, F., Baron-Hay, S., Park, S. (2017). Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 128(7), 1166-1175. [More Information]
• McCrary, J., Goldstein, D., Boyle, F., Cox, K., Grimison, P., Kiernan, M., Krishnan, A., Lewis, C., Webber, K., Baron-Hay, S., Horvath, L., Park, S. (2017). Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 25(11), 3485-3493. [More Information]
• Simon, N., Lagopoulos, J., Paling, S., Pfluger, C., Park, S., Howells, J., Gallagher, T., Kliot, M., Henderson, R., Vucic, S., Kiernan, M. (2017). Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 264(5), 882-890. [More Information]
• Shibuya, K., Simon, N., Geevasinga, N., Menon, P., Howells, J., Park, S., Huynh, W., Noto, Y., Vucic, S., Kiernan, M. (2017). The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 128, 1075-1082. [More Information]
• Park, S., Baker, M. (2017). Too fast: Rare neuropathic pain state associated with easy activation of NaV1.9. Journal of Neurology, Neurosurgery and Psychiatry, 88(3), 194. [More Information]

2016

• Garg, N., Yuki, N., Park, S., Barnett, M., Kiernan, M. (2016). Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: A rare localized subtype of Guillain-Barre sydnrome. Muscle and Nerve, 53(1), 143-146. [More Information]
• Park, S., Lin, C., Kiernan, M. (2016). Axonal excitability: molecular basis and assessment in the clinic. In Kerry R. Mills (Eds.), Oxford Textbook of Clinical Neurophysiology, (pp. 97-105). Oxford: Oxford University Press. [More Information]
• Park, S., Davare, M., Falla, M., Kennedy, W., Selim, M., Wendelschafer-Crabb, G., Koltzenburg, M. (2016). Fast Adapting Mechanoreceptors are Important for Force Control in Precision Grip but not for Sensorimotor Memory. Journal of Neurophysiology, 115(6), 3156-3161. [More Information]
• Shibuya, K., Park, S., Geevasinga, N., Menon, P., Howells, J., Simon, N., Huynh, W., Noto, Y., Gotz, J., Kril, J., Vucic, S., Kiernan, M., et al (2016). Motor cortical function determines prognosis in sporadic ALS. Neurology, 87(5), 513-520. [More Information]
• Kandula, T., Park, S., Cohn, R., Krishnan, A., Farrar, M. (2016). Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treatment Reviews, 50, 118-128. [More Information]
• Shibuya, K., Park, S., Geevasinga, N., Huynh, W., Simon, N., Menon, P., Howells, J., Vucic, S., Kiernan, M. (2016). Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. Clinical Neurophysiology, 127(6), 2355-2361. [More Information]

2015

• Mathey, E., Park, S., Hughes, R., Pollard, J., Armati, P., Barnett, M., Taylor, B., Dyck, J., Kiernan, M., Lin, C. (2015). Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 86(9), 973-985. [More Information]
• Park, S., Vucic, S., Cheah, B., Lin, C., Kirby, A., Robledo, K., Zoing, M., Winhammar, J., Kiernan, M. (2015). Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2(12), 1916-1922. [More Information]
• Park, S., Sung, J., Tani, J., Kiernan, M., Lin, C. (2015). Reply: biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 138(3), 1-2. [More Information]

2014

• Park, S., Lin, C., Krishnan, A., Simon, N., Bostock, H., Vincent, A., Kiernan, M. (2014). Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 261, 337-342. [More Information]
• Farrar, M., Park, S., Krishnan, A., Kiernan, M., Lin, C. (2014). Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 49(6), 858-865. [More Information]
• Park, S., Krishnan, A. (2014). Chemotherapy-induced peripheral neuropathy: the end of the beginning? Journal of Neurology, Neurosurgery and Psychiatry, 85(4), 359-359. [More Information]
• Sung, J., Tani, J., Park, S., Kiernan, M., Lin, C. (2014). Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 137(8), 2155-2163. [More Information]
• Park, S., Kwok, J., Loy, C., Friedlander, M., Lin, C., Krishnan, A., Lewis, C., Kiernan, M. (2014). Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 14, 1-5. [More Information]
• Park, S. (2014). The clinical relevance of voltage gated potassium channel (VGKC)-complex antibodies: the story is still unfolding. Journal of Neurology, Neurosurgery and Psychiatry, 85(6), 596-596. [More Information]

2013

• Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
• Farrar, M., Park, S., Lin, C., Kiernan, M. (2013). Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. Journal of Physiology, 591(1), 273-286. [More Information]
• Lin, C., Park, S., Krishnan, A. (2013). Porphyric neuropathy. In Gerard Said and Christian Krarup (Eds.), Handbook of Clinical Neurology: Vol 115 Peripheral Nerve Disorders, (pp. 613-627). Amsterdam: Elsevier. [More Information]

2012

• Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
• Krishnan, A., Park, S., Huynh, W., Lin, C., Henderson, R., Kiernan, M. (2012). Impaired energy-dependent processes underlie acute lead neuropathy. Muscle and Nerve, 46(6), 954-956. [More Information]
• Park, S., Lin, C., Kiernan, M., Koltzenburg, M. (2012). Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology, 78(2), 152. [More Information]
• Park, S., Lin, C., Kiernan, M. (2012). Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 62, 3439. [More Information]
• Cheah, B., Lin, C., Park, S., Vucic, S., Krishnan, A., Kiernan, M. (2012). Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 123(12), 2460-2467. [More Information]
• Sung, J., Park, S., Liu, Y., Kwai, N., Arnold, R., Krishnan, A., Lin, C. (2012). Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes, 61(6), 1592-1598. [More Information]

2011

• Park, S., Lin, C., Burke, D., Kiernan, M. (2011). Activity-dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 16(3), 159-168. [More Information]
• Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
• Farrar, M., Vucic, S., Lin, C., Park, S., Johnston, H., du Sart, D., Bostock, H., Kiernan, M. (2011). Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 134(11), 3185-3197. [More Information]
• Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-374. [More Information]
• Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
• Lin, C., Krishnan, A., Park, S., Kiernan, M. (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. JAMA Neurology, 68(7), 862-869. [More Information]
• Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
• Lin, C., Lee, M., Park, S., Kiernan, M. (2011). Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 122(12), 2336-2344. [More Information]
• Krishnan, A., Park, S., Payne, M., Lin, C., Vucic, S., Kiernan, M. (2011). Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 122(1), 194-198. [More Information]
• Park, S., Lin, C., Krishnan, A., Kiernan, M. (2011). The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Cancer Chemotherapy and Pharmacology, 67(5), 1189-1190. [More Information]
• Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]

2010

• Farrar, M., Lin, C., Krishnan, A., Park, S., Andrews, P., Kiernan, M. (2010). Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 126(3), e734-e739. [More Information]
• Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2010). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Oncology, 77(6), 342-348. [More Information]

2009

• Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
• Krishnan, A., Lin, C., Park, S., Kiernan, M. (2009). Axonal ion channels from bench to bedside: a translational neuroscience perspective. Progress in Neurobiology, 89(3), 288-313. [More Information]
• Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 132(10), 2712-2723. [More Information]

2008

• Krishnan, A., Lin, C., Park, S., Kiernan, M. (2008). Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 13(1), 7-26. [More Information]
• Park, S., Krishnan, A., Lin, C., Goldstein, D., Friedlander, M., Kiernan, M. (2008). Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Current Medicinal Chemistry, 15(29), 3081-3094. [More Information]

2007

• Gulledge, A., Park, S., Kawaguchi, Y., Stuart, G. (2007). Heterogeneity of phasic cholinergic signaling in neocortical neurons. Journal of Neurophysiology, 97(3), 2215-2229. [More Information]